Every American aged 75 or older should receive a single dose of RSV vaccine ahead of the 2024-2025 respiratory season, according to a recommendation the CDC adopted after its advisory panel voted on June 26, 2024. The decision replaces an earlier approach that left the choice up to individual conversations between patients and their doctors. With RSV sending tens of thousands of older adults to hospitals each winter, the shift to a universal recommendation for the oldest age group carries direct consequences for how quickly vaccination rates climb before cases begin to surge.
Why a universal RSV vaccine recommendation for adults 75 and older matters right now
Until this summer, RSV vaccination for older adults operated under what the CDC called “shared clinical decision-making.” That framework asked doctors and patients to weigh individual risk factors before deciding whether to vaccinate. In practice, shared decision-making often produced confusion and low uptake, because neither patients nor busy clinicians had a clear directive. The advisory panel’s June 26 vote, documented in an official meeting record, eliminated that ambiguity for people 75 and older by making the recommendation universal: every adult in that age group should get a single dose of any FDA-approved RSV vaccine.
The timing is deliberate. RSV activity in the United States typically accelerates in late fall and peaks during winter. A universal recommendation issued in the summer gives pharmacies, health systems, and insurers several months to prepare supply chains and outreach before the virus circulates widely. If uptake among adults 75 and older reaches meaningful levels before December, CDC surveillance systems could detect a measurable reduction in RSV-related ICU admissions among that group by early 2025. That hypothesis depends on whether the shift from optional to universal guidance actually changes behavior at the pharmacy counter and in primary care offices.
The recommendation also simplifies messaging for clinicians. Instead of parsing individual risk profiles for every patient over 75, providers can treat RSV vaccination similarly to annual influenza shots for older adults: a standard part of fall preventive care. For patients, the universal language removes the impression that RSV vaccination is experimental or only for people with unusual medical histories. Clear, categorical guidance tends to support higher uptake when paired with easy access and insurance coverage.
ACIP’s evidence base and the three licensed vaccines
The recommendation covers all three RSV vaccines currently licensed by the FDA for older adults. GSK’s Arexvy and Pfizer’s Abrysvo were the first to reach the market, and Moderna’s mRESVIA received FDA approval on May 31, 2024, for adults aged 60 and older. ACIP’s updated guidance allows clinicians to use any of these products for the 75-and-older population, giving providers flexibility based on availability and patient preference.
ACIP built its case on pooled trial data reviewed through its formal GRADE (Grading of Recommendations Assessment, Development and Evaluation) process, which assessed vaccine efficacy against RSV-associated lower respiratory tract disease in older adult subgroups. The committee’s analysis focused on outcomes that matter most for frail patients: medically attended lower respiratory infections, hospitalizations, and severe disease. Across trials, vaccine efficacy against symptomatic lower respiratory tract disease was substantial in the first RSV season after vaccination, including in participants 75 and older.
The committee’s Evidence to Recommendations framework also weighed benefits against potential harms, including a rare but documented safety signal: cases of Guillain-Barré syndrome identified in post-licensure monitoring. Investigators examined incidence rate ratios and background rates of this neurologic condition. While the signal prompted caution, ACIP concluded that the benefits of vaccination in adults 75 and older outweighed the risks, given the severe burden RSV places on that age group each season. Older adults have higher baseline risks of hospitalization, respiratory failure, and death from RSV, so even modest reductions in severe disease can translate into meaningful numbers of averted ICU stays.
For adults between 60 and 74, ACIP took a narrower path. The committee recommended RSV vaccination for this younger group only when patients have conditions that raise their odds of severe disease, such as chronic lung or heart conditions, weakened immune systems, or residence in nursing facilities. The CDC’s own page for older adult RSV risk also references adults aged 50 to 74 at increased risk as candidates for vaccination, though the ACIP vote specifically addressed adults 60 to 74 at increased risk. That discrepancy between the broader 50-74 language on some CDC pages and the 60-74 scope of the ACIP vote has not been fully reconciled in public-facing materials, potentially complicating counseling for people in their early 60s who have chronic conditions.
Clinically, the split recommendation means providers must maintain two mental checklists. For anyone 75 or older, the answer is straightforward: offer a single RSV vaccine dose, regardless of other medical issues. For those 60 to 74, clinicians need to assess comorbidities and living situations to decide whether RSV vaccination is appropriate. That nuance may be harder to implement in busy pharmacies and urgent care clinics, where age-based rules are simpler to operationalize than risk-based ones.
Coverage gaps, safety monitoring, and what to watch this fall
Several questions remain open as the respiratory season approaches. No primary CDC dataset yet tracks post-June 2024 vaccination uptake rates specifically among adults 75 and older, so there is no early signal on whether the universal recommendation is translating into shots administered. State-level hospitalization baselines for the 2024-2025 RSV season have not been published, which limits the ability to measure the recommendation’s impact in real time. And neither the MMWR report nor the ACIP decision documents include data on insurance coverage rates or out-of-pocket costs for these vaccines, a gap that could slow uptake if older adults face unexpected bills.
Equity in access is another blind spot. The ACIP Evidence to Recommendations framework considered feasibility and equity, but primary sources do not contain granular analyses of vaccine access by race, income, or rural residence. Past respiratory vaccine campaigns have shown persistent disparities along all three of those lines, and there is no published plan detailing how the CDC or state health departments intend to close those gaps for RSV specifically. Without targeted outreach, older adults in communities with fewer clinicians or pharmacies could lag behind, even as national averages improve.
The Guillain-Barré signal also remains under active review. FDA labeling for Abrysvo includes warnings about the condition, and ACIP’s decision documents acknowledge the signal without declaring it resolved. Ongoing post-market surveillance will determine whether the risk estimate changes as more doses are administered. Systems like the Vaccine Adverse Event Reporting System and other CDC safety platforms, accessible through the agency’s main public health site, will be central to monitoring these outcomes during the upcoming season.
For adults 75 and older who have not yet received an RSV vaccine, the practical takeaway is straightforward: plan to get a single dose before RSV activity ramps up in late fall, ideally at the same visit as influenza or COVID-19 vaccination if a clinician deems coadministration appropriate. For clinicians, the new guidance offers an opportunity to standardize RSV vaccination as part of routine care for the oldest patients, while still using individualized judgment for those in their 60s and early 70s.
How well the recommendation performs will become clearer over the next year. If pharmacies and clinics can translate a universal rule into high coverage, surveillance data should eventually show fewer RSV hospitalizations and deaths among adults 75 and older. If coverage remains patchy, especially in underserved communities, the clinical promise of these vaccines may be realized unevenly. For now, the policy shift marks a significant step: RSV vaccination for the oldest Americans has moved from a case-by-case option to a standard expectation of preventive care.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
